Multiantigenic subunitary vaccines against tuberculosis in clinical trials: Where do we stand and where do we need to go?

被引：4
作者：
Guapillo, Carolina [1 ]
Hernandez-Pando, Rogelio [1 ]
Alberto Flores-Valdez, Mario [2 ]
机构：
[1] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Patol, Secc Patol Expt, Mexico City, DF, Mexico
[2] Ctr Invest & Asistencia Tecnol & Diseno Estado Ja, Biotecnol Med & Farmaceut, Ave Normalistas 800, Guadalajara 44270, Jalisco, Mexico
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2016年 / 12卷 / 05期
关键词：
clinical trials; multiantigenic; tuberculosis; vaccines; MYCOBACTERIUM-TUBERCULOSIS; NEGATIVE ADULTS; IMMUNOGENICITY; MTB72F/AS02; ANTIGENS; HUMANS; SAFETY;
D O I：
10.1080/21645515.2015.1136760
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
The idea of presenting this commentary is to bring attention to the current status of clinical tests from several multiantigen vaccine candidates based on proteins produced by means of genetic engineering and molecular biology approaches and to suggest how new emerging technologies (OMICs) and bioinformatics might benefit vaccine development for better control of tuberculosis.
引用
收藏
页码：1193 / 1195
页数：3
相关论文
共 50 条
[31]   Sorafenib: Where Do We Go from Here? [J].
Siegel, Abby B. ;
Olsen, Sonja K. ;
Magun, Arthur ;
Brown, Robert S., Jr. .
HEPATOLOGY, 2010, 52 (01) :360-369
[32]   CLARITHROMYCIN - WHERE DO WE GO FROM HERE [J].
KLEIN, JO .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1993, 12 (12) :S148-S151
[33]   Irreversible Electroporation in Interventional Oncology: Where We Stand and Where We Go [J].
Savic, L. J. ;
Chapiro, J. ;
Hamm, B. ;
Gebauer, B. ;
Collettini, F. .
ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 2016, 188 (08) :735-745
[34]   Early Termination of Cardiovascular Clinical Trials Registered in ClinicalTrials.gov: Where Do We Stand? [J].
Pereira, Sabrina B. ;
Lopes, Renato D. ;
Carrion, Maria Julia ;
Santucci, Eliana V. ;
Soares, Rafael M. ;
Abreu, Matheus O. ;
Laranjeira, Ligia N. ;
Ikeoka, Dimas T. ;
Zazula, Ana ;
Moreira, Frederico R. ;
Cavalcanti, Alexandre B. ;
Mesquita, Evandro T. ;
Peterson, Eric D. ;
Califf, Robert M. ;
Berwanger, Otavio .
CIRCULATION, 2013, 128 (22)
[35]   Practice Quality Improvement During Residency: Where Do We Stand and Where Can We Improve? [J].
Choudhery, Sadia ;
Richter, Michael ;
Anene, Alvin ;
Xi, Yin ;
Browning, Travis ;
Chason, David ;
Morriss, Michael Craig .
ACADEMIC RADIOLOGY, 2014, 21 (07) :851-858
[36]   Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When We're There? [J].
Auld, Sara C. ;
Kasmar, Anne G. ;
Dowdy, David W. ;
Mathema, Barun ;
Gandhi, Neel R. ;
Churchyard, Gavin J. ;
Rustomjee, Roxana ;
Shah, N. Sarita .
JOURNAL OF INFECTIOUS DISEASES, 2017, 216 :S662-S668
[37]   Viral Vectors in Gene Therapy: Where Do We Stand in 2023? [J].
Lundstrom, Kenneth .
VIRUSES-BASEL, 2023, 15 (03)
[38]   Drug Repurposing for the Management of Depression: Where Do We Stand Currently? [J].
Mohammad Sadeghi, Hosna ;
Adeli, Ida ;
Mousavi, Taraneh ;
Daniali, Marzieh ;
Nikfar, Shekoufeh ;
Abdollahi, Mohammad .
LIFE-BASEL, 2021, 11 (08)
[39]   Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Terapy [J].
Iannuzzo, Gabriella ;
Tripaldella, Maria ;
Mallardo, Vania ;
Morgillo, Mena ;
Vitelli, Nicoletta ;
Iannuzzi, Arcangelo ;
Aliberti, Emilio ;
Giallauria, Francesco ;
Tramontano, Anna ;
Carluccio, Raffaele ;
Calcaterra, Ilenia ;
Di Minno, Matteo Nicola Dario ;
Gentile, Marco .
BIOMEDICINES, 2021, 9 (07)
[40]   Trophic factors for Parkinson's disease: Where are we and where do we go from here? [J].
Paul, Gesine ;
Sullivan, Aideen M. .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2019, 49 (04) :440-452
12345